MAXCYTE INC (MXCT)

MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024

MXCT stock results show that MaxCyte beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

MXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips MaxCyte (NASDAQ:MXCT) just reported results for the first quarter of 2024.MaxCy...

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

ROCKVILLE, Md., April 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing...

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs...

Commit To Buy MaxCyte At $2.50, Earn 6.7% Annualized Using Options

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

MaxCyte is Now Oversold (MXCT)

MXCT Makes Notable Cross Below Critical Moving Average

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing...

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers...

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer along with additional novel cell therapy programs

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T...

MaxCyte says Q4 revenue is expected to be between $15.5M and $15.7M (NASDAQ:MXCT)

MaxCyte expects total revenue for Q4 2023 to be $15.5-15.7M, up from $12.4M in Q4 2022.

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results

MaxCyte and Lion TCR join hands for Lion TCR's global expansion (NASDAQ:MXCT)

MaxCyte and Lion TCR signed a strategic platform license, enhancing MaxCyte's presence in Asia and expanding into the US and European markets.

MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline

Lion TCR to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to develop and scale TCR-T cell therapies for solid tumors and viral-related diseases.

MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline

Lion TCR to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to develop and scale TCR-T cell therapies for solid tumors and...

MaxCyte gets new CEO and President (NASDAQ:MXCT)

MaxCyte, a cell-engineering company, appoints Maher Masoud as President and CEO, effective from January 2024.

MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director

MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director

ROCKVILLE, Md., Jan. 01, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing...

MaxCyte announces departure of founder and CEO Doug Doerfler (NASDAQ:MXCT)

MaxCyte appoints Maher Masoud as CEO, exceeding revenue guidance for 2023.